Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota - a Randomized Controlled Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 56
- 试验地点
- 4
- 主要终点
- Hepatic stellate cell activity
研究概览
简要总结
Investigators wishes to influence the gut microbiota in patients with alcoholic liver disease in a randomized controlled clinical trial. The investigators hypothesize that the alcohol-related dysbiosis seen in these patients can be changed and disease progression haltered by modulating microbiota with probiotics during 24 weeks.
详细描述
Chronic alcohol overuse is associated with increased gut permeability and in addition, the intestinal microbiota changes qualitatively (dysbiosis) and quantitatively (bacterial overgrowth) in alcoholic liver disease in favour of a microbiota with increased invasive potential. As a consequence, an increased load of bacterial products is transported to the liver leading to inflammation and fibrogenesis.
This cross talk between the intestinal microbiota and the liver constitute a gut-liver axis, which is increasingly recognized as key mechanism in the progression of liver disease and pathogenesis of liver related complications.
The investigators hypothesize that the gut microbiota and its metabolites are major drivers of fibrosis in human liver disease and that modulating the intestinal flora by Profermin® (a food for special medical purposes) will modulate the alcohol related dysbiotic signatures in the microbiota which may halter disease progression by reducing activity of hepatic stellate cells.
Dietary supplements that alter the microbiome towards a more beneficent type may improve liver inflammation and thus be a better alternative than supplements that simply add nutrients. Investigators expect that the trial will provide proof-of-concept for a sustainable dietary strategy in liver fibrosis.
Examples of biopsies which did not meet quality criteria for reliable histological reading, led to inclusion of 16 extra patients. In total we included 56 patients to ensure an adequate number of participants with valid liver biopsy data for assessment of the primary endpoint and intention-to-treat analysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
盲法说明
Pathologist will perform outcome assessment blinded
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prior or ongoing harmful alcohol intake defined as an average of ≥24g alcohol/day for women and ≥36g/d for men for ≥ 5 year.
- •Outpatients with compensated advanced chronic alcohol-related liver disease, defined as stable patients with:
- •liver stiffness ≥15 kPa and asymptomatic and/or
- •New liver biopsy (<6months) with at least F3 fibrosis (kleiner) and/or
- •Liver biopsy older that 6 months with liver stiffness ≥10 kPa
- •Understand and speak Danish written and orally
- •Informed consent
排除标准
- •Hospitalised
- •Moderete or severe Ascites, determined from imaging diagnostics
- •High-risk varices needing interventional treatment (endoscopy, TIPS)
- •Child-Pugh C score
- •MELD-Na ≥15
- •Lactose intolerance
- •Coeliac disease
- •Irritable bowel syndrome defined by ROME III criteria
- •Antibiotic treatment the prior 3 months
- •Treatment with nutritional drinks, probiotics or prebiotics within the last 3 months
- •The investigator judge that the patient would not be compliant with trial medicine
- •Pregnancy
- •Known liver disease other than alcoholic, of any aetiology
- •Severe malnutrition
- •Malignancy - except spino- or basocellular skin cancer. Patients with prior malignant disease are allowed if cancer-free for at least one year
- •Recent infectious gastroenteritis (for the last 6 weeks)
结局指标
主要结局
Hepatic stellate cell activity
时间窗: 24 weeks
Attenuation of liver hepatic stellate cell activity, defined as the proportion of patients with a 10% or more reduction in activated hepatic stellate cells, measured by a-smooth muscle actin (a-SMA) stain quantification of liver biopsies.
次要结局
- Hepatic a-SMA activity(24 weeks)
- Reduction in non-invasive fibrosis marker(24 weeks)
- Hepatic inflammation(24 weeks)
- Alfa-smooth muscle actin concentration(24 weeks)
- Hepatic venous pressure gradient (HVPG)(24 weeks)
- Improvement in gut dysbiosis(24 weeks)
- Markers of liver inflammation(24 weeks)
- Metabolic changes(24 weeks)
- Liver vein outflow of microbial products(24 weeks)
- Any changes in non-invasive markers of steatosis(24 weeks)
- Individual domains of NAS scoring systemt(24 weeks)
- Changes in hepatic macrophage activity(24 weeks)
- Improvement of liver histological lesions(24 weeks)
- Changes bile acids(24 weeks)
- Lipid profile(24 weeks)
- Changes in circulating cytokines(24 weeks)
- Reduction in non-invasive fibrosis markers(24 weeks)
- Changes in intestinal fibrosis markers(24 weeks)
研究者
Aleksander Krag
Professor, PhD, Cand.Med.
Odense University Hospital